Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31139826 | 0.79 | — | — | |
| SCHEMBL9332066 | 0.71 | GRM4 (0.48) | — | |
| SCHEMBL12932503 | 0.69 | — | — | |
| SCHEMBL2642564 | 0.69 | — | — | |
| SCHEMBL6181092 | 0.69 | — | — | |
| SCHEMBL2642899 | 0.67 | — | — | |
| SCHEMBL9602973 | 0.67 | — | — | |
| SCHEMBL11443222 | 0.67 | — | — | |
| SCHEMBL2642561 | 0.67 | — | — | |
| SCHEMBL5610047 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111138810-B | UV patternable polymer blend for organic thin film transistor | 康宁股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2024-05-14 | — | — | US | disclosed |
| CN-118001282-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11917897-B2 | Photo-patternable organic semiconductor (OSC) polymers for organic thin-film transistors | CORNING INCORPORATED (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117222235-A | Pseudo-homogeneous photopatternable semiconducting polymer blends for Organic Thin Film Transistors (OTFTs) | 康宁股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023235181-A1 | PSEUDO-HOMOGENEOUS PHOTO-PATTERNABLE SEMICONDUCTING POLYMER BLENDS FOR ORGANIC THIN-FILM TRANSISTORS (OTFT) | CORNING INCORPORATED (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-111770926-B | Tricyclic compounds, compositions and pharmaceutical uses thereof | 因佩蒂斯生物科学有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11643379-B2 | Synthesis of branched alkyl alcohols by Cu(I)-catalyzed C-C coupling between alkyl Grignard reagents and alkyl tosylates | CORNING INCORPORATED (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| CN-110730791-B | Doping of organic semiconducting polymers with other polymers | 康宁股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-6713650-B2 | ELEVATES ATP BINDING CASSETTE TRANSPORTER 1 EXPRESSION THEREBY INCREASING EFFLUX OF CHOLESTEROL FROM CELLS BY ACTIVE TRANSFER INTO HIGH DENSITY LIPOPROTEINS | CV THERAPEUTICS, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1377283-A2 | COMPOUNDS OF THE FORMULA R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003103651-A1 | COMPOUNDS OF THE FORMU;A R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CAD OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| US-20020082257-A1 | ABCA-1 Elevating compounds | CV THERAPEUTICS, INC. | 2002-06-27 | — | — | US | disclosed |
| WO-2002046141-A2 | COUMPOUNDS OF THE FORMULA R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA1, ADORA2B | PDE2A 232/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PDE2A 127/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PDE2A 127/4885 |
| US-11643379-B2 | Synthesis of branched alkyl alcohols by Cu(I)-catalyzed C-C coupling between alkyl Grignard reagents and alkyl tosylates | ADH1C, UGCG, ADH1A | PDE2A 4025/4885 |
| US-20020082257-A1 | ABCA-1 Elevating compounds | ABCD3, ABCE1, ABCB4 | PDE2A 2024/4885 |
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | PDE2A 156/4885 |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | ADORA2A, ADORA1, ADORA2B | PDE2A 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.